Nephros PE Ratio 2010-2025 | NEPH
Current and historical p/e ratio for Nephros (NEPH) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Nephros PE ratio as of August 14, 2025 is 34.33.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Nephros PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-08-14 | 4.00 | 33.33 | |
| 2025-06-30 | 4.09 | $0.12 | 34.08 |
| 2025-03-31 | 1.72 | $0.07 | 24.57 |
| 2024-12-31 | 1.47 | $0.00 | 0.00 |
| 2024-09-30 | 1.71 | $-0.09 | 0.00 |
| 2024-06-30 | 2.11 | $-0.13 | 0.00 |
| 2024-03-31 | 2.19 | $-0.14 | 0.00 |
| 2023-12-31 | 3.46 | $-0.15 | 0.00 |
| 2023-09-30 | 1.48 | $-0.09 | 0.00 |
| 2023-06-30 | 1.55 | $-0.38 | 0.00 |
| 2023-03-31 | 1.07 | $-0.46 | 0.00 |
| 2022-12-31 | 1.16 | $-0.63 | 0.00 |
| 2022-09-30 | 0.91 | $-0.74 | 0.00 |
| 2022-06-30 | 1.53 | $-0.55 | 0.00 |
| 2022-03-31 | 4.40 | $-0.55 | 0.00 |
| 2021-12-31 | 5.90 | $-0.41 | 0.00 |
| 2021-09-30 | 8.77 | $-0.38 | 0.00 |
| 2021-06-30 | 10.15 | $-0.38 | 0.00 |
| 2021-03-31 | 6.65 | $-0.45 | 0.00 |
| 2020-12-31 | 8.58 | $-0.52 | 0.00 |
| 2020-09-30 | 7.23 | $-0.46 | 0.00 |
| 2020-06-30 | 8.39 | $-0.44 | 0.00 |
| 2020-03-31 | 6.30 | $-0.39 | 0.00 |
| 2019-12-31 | 9.95 | $-0.44 | 0.00 |
| 2019-09-30 | 8.05 | $-0.51 | 0.00 |
| 2019-06-30 | 5.49 | $-0.50 | 0.00 |
| 2019-03-31 | 4.32 | $-0.45 | 0.00 |
| 2018-12-31 | 5.13 | $-0.54 | 0.00 |
| 2018-09-30 | 5.43 | $-0.27 | 0.00 |
| 2018-06-30 | 5.47 | $-0.27 | 0.00 |
| 2018-03-31 | 3.78 | $-0.27 | 0.00 |
| 2017-12-31 | 4.05 | $-0.09 | 0.00 |
| 2017-09-30 | 2.70 | $-0.36 | 0.00 |
| 2017-06-30 | 2.07 | $-0.36 | 0.00 |
| 2017-03-31 | 3.46 | $-0.45 | 0.00 |
| 2016-12-31 | 3.29 | $-0.54 | 0.00 |
| 2016-09-30 | 3.33 | $-0.63 | 0.00 |
| 2016-06-30 | 2.31 | $-0.72 | 0.00 |
| 2016-03-31 | 2.34 | $-1.08 | 0.00 |
| 2015-12-31 | 1.94 | $-1.08 | 0.00 |
| 2015-09-30 | 3.33 | $-2.88 | 0.00 |
| 2015-06-30 | 6.39 | $-2.97 | 0.00 |
| 2015-03-31 | 5.40 | $-2.70 | 0.00 |
| 2014-12-31 | 7.11 | $-2.88 | 0.00 |
| 2014-09-30 | 6.98 | $-1.53 | 0.00 |
| 2014-06-30 | 10.62 | $-1.53 | 0.00 |
| 2014-03-31 | 5.76 | $-1.71 | 0.00 |
| 2013-12-31 | 3.82 | $-2.25 | 0.00 |
| 2013-09-30 | 10.80 | $-2.43 | 0.00 |
| 2013-06-30 | 8.10 | $-2.79 | 0.00 |
| 2013-03-31 | 7.11 | $-2.97 | 0.00 |
| 2012-12-31 | 10.71 | $-2.52 | 0.00 |
| 2012-09-30 | 12.60 | $-2.25 | 0.00 |
| 2012-06-30 | 18.00 | $-1.98 | 0.00 |
| 2012-03-31 | 9.45 | $-1.89 | 0.00 |
| 2011-12-31 | 6.21 | $-3.06 | 0.00 |
| 2011-09-30 | 17.10 | $-10.62 | 0.00 |
| 2011-06-30 | 6.75 | $-12.06 | 0.00 |
| 2011-03-31 | 3.96 | $-13.32 | 0.00 |
| 2010-12-31 | 18.00 | $-13.50 | 0.00 |
| 2010-09-30 | 50.40 | $-7.20 | 0.00 |
| 2010-06-30 | 64.80 | $-7.20 | 0.00 |
| 2010-03-31 | 198.00 | $-7.20 | 0.00 |
| 2009-12-31 | 140.40 | $-5.40 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.044B | $0.014B |
| Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $225.215B | 26.41 |
| Boston Scientific (BSX) | United States | $151.880B | 36.22 |
| Stryker (SYK) | United States | $144.875B | 29.49 |
| EssilorLuxottica (ESLOY) | France | $142.491B | 0.00 |
| Medtronic (MDT) | Ireland | $119.092B | 16.89 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.952B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.526B | 24.85 |
| ResMed (RMD) | United States | $42.208B | 30.19 |
| GE HealthCare Technologies (GEHC) | United States | $34.393B | 16.17 |
| Agilent Technologies (A) | United States | $34.170B | 22.28 |
| Terumo (TRUMY) | Japan | $27.923B | 33.09 |
| Koninklijke Philips (PHG) | Netherlands | $26.278B | 17.38 |
| Insulet (PODD) | United States | $21.729B | 72.80 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.447B | 13.02 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.109B | 0.00 |
| Baxter (BAX) | United States | $12.383B | 9.57 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.771B | 28.55 |
| Lantheus Holdings (LNTH) | United States | $3.657B | 9.89 |
| Envista Holdings (NVST) | United States | $3.583B | 25.07 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.269B | 14.50 |
| Perrigo (PRGO) | Ireland | $3.255B | 8.13 |
| ICU Medical (ICUI) | United States | $2.817B | 19.18 |
| Haemonetics (HAE) | United States | $2.596B | 11.59 |
| LeMaitre Vascular (LMAT) | United States | $2.154B | 46.19 |
| Curaleaf Holdings (CURLF) | Canada | $2.065B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.899B | 81.54 |
| QuidelOrtho (QDEL) | United States | $1.839B | 11.57 |
| AtriCure (ATRC) | United States | $1.824B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.376B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.316B | 18.75 |
| Phibro Animal Health (PAHC) | United States | $1.255B | 16.04 |
| BioLife Solutions (BLFS) | United States | $1.230B | 2568.00 |
| Neogen (NEOG) | United States | $1.203B | 19.10 |
| Acuren (TIC) | United States | $1.169B | 0.00 |
| Valneva SE (VALN) | France | $0.950B | 0.00 |
| InMode (INMD) | Israel | $0.926B | 8.57 |
| Kestra Medical Technologies (KMTS) | United States | $0.816B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.700B | 0.00 |
| SNDL (SNDL) | Canada | $0.562B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.547B | 0.00 |
| Surmodics (SRDX) | United States | $0.543B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.532B | 0.00 |
| ZimVie (ZIMV) | United States | $0.532B | 20.49 |
| VAREX IMAGING (VREX) | United States | $0.444B | 15.27 |
| CeriBell (CBLL) | United States | $0.437B | 0.00 |
| Evolus (EOLS) | United States | $0.421B | 0.00 |
| Owens & Minor (OMI) | United States | $0.412B | 3.65 |
| Capricor Therapeutics (CAPR) | United States | $0.379B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.342B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.336B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.330B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.312B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.284B | 21.56 |
| Sanara MedTech (SMTI) | United States | $0.284B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.272B | 0.00 |
| Omeros (OMER) | United States | $0.264B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.262B | 0.00 |
| Cerus (CERS) | United States | $0.255B | 0.00 |
| Brainsway (BWAY) | Israel | $0.240B | 48.85 |
| Quanterix (QTRX) | United States | $0.223B | 0.00 |
| Organigram Global (OGI) | Canada | $0.214B | 0.00 |
| Exagen (XGN) | United States | $0.213B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.208B | 0.00 |
| High Tide (HITI) | Canada | $0.200B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.190B | 15.88 |
| Biote (BTMD) | United States | $0.168B | 5.03 |
| FitLife Brands (FTLF) | United States | $0.152B | 18.75 |
| TriSalus Life Sciences (TLSI) | United States | $0.149B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.128B | 0.00 |
| MacroGenics (MGNX) | United States | $0.105B | 0.00 |
| Jin Medical (ZJYL) | China | $0.102B | 0.00 |
| Fonar (FONR) | United States | $0.095B | 12.19 |
| Apyx Medical (APYX) | United States | $0.089B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.088B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Safety Shot (SHOT) | United States | $0.076B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| MariMed (MRMD) | United States | $0.051B | 0.00 |
| Veru (VERU) | United States | $0.050B | 0.00 |
| Zynex (ZYXI) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.39 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.018B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |